Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 33Neoplasms 18Colorectal Neoplasms 3Skin Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Skin Diseases 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Cancer Metastatic 1Biliary Tract Neoplasms 1Advanced BRAF-mutant Cancers 1

Interventions

aflibercept 6Oxaliplatin 3Leucovorin 3Irinotecan 3Fluorouracil 2Capecitabine 2Bevacizumab 2trifluridine tipiracil drug combination 1raltitrexed 1monoclonal antibody YYB-101 1masitinib 1atezolizumab 1Vemurafenib 1Panitumumab 1Nivolumab 1IFL protocol 1HMPL-013 1Ethiodized Oil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Colorectal Cancer Metastatic × Vemurafenib × Clear all
NCT06008119 2025-09-18

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Shanghai Kechow Pharma, Inc.

Phase 3 Recruiting
165 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡